I am just trying to understand what if anything the aviptadil data may offer to help predict what the CD12 placebo population mortality is.

I cant make any sense of it.

I was responding to a post that suggested aviptadil placebo patients were sicker so thus more likely to die.

But at least 11 of the 35 reported placebo patients were healthy enough that they qualified for the trial, so those 11 patients were relatively healthier than the aviptadil expanded access patients.

If BPRA filing is factually correct, 10 of those placebo trial patients died.

So the mortality rate of the healthiest patients to receive aviptadil is 10/11 91% at 77 days?

If so, aviptadil and LL are not treating the same patients, and thus aviptadil placebo mortality has no relation to CD12 placebo mortality.

I am hoping someone knows something about those aviptadil trials so that they can be compared to CD12.